Call Today

(April 24, 2024) Webinar: Accelerating the Delivery of New Treatments for Children with Neuroblastoma with the MRI-Guided Paediatric Mouse Hospital

(April 24, 2024) Webinar: Accelerating the Delivery of New Treatments for Children with Neuroblastoma with the MRI-Guided Paediatric Mouse Hospital

Register

Neuroblastoma is a tumour arising from anomalies in the development of the sympathic nervous system and still accounts for 13% of all cancer-related death in children due to resistant, relapsing and metastatic diseases. There is an urgent need for the development of new treatment against high-risk relapsed neuroblastoma.

Overview:

Here we will discuss the ICR Paediatric Mouse Hospital approach which integrates more advanced mouse modelling, such as the use of genetically-engineered mouse (GEM) models and patient-derived xenografts to accelerate the discovery and evaluation of novel therapeutic strategies and help shape the clinical trial pipeline priorities for children with high-risk relapsing/refractory neuroblastoma.

We will also highlight the pivotal role of MRI within the Mouse Hospital which includes:

  • Enhancing and accelerating preclinical trials
  • Quantitatively inform on tumour phenotype and tumour response to treatment to:
    • Develop in vivo models that emulate the clinical treatment resistant phenotype using chemotherapy-dose escalation protocol
    • Characterize tumour spatial heterogeneity and evolution over treatment and guide the pathological and molecular characterization of the resistant phenotype

 

Finally we will also discuss how the compact, cryogen-free and user-friendly Aspect Imaging M-Series has transformed our way of working within the mouse hospital by providing a shared and easily accessible resource for tumour screening (with minimal onboarding) .

Date

Apr 24 2024
Expired!
11:00 am - 12:00 pm

Speakers

  • Dr. Yann Jamin, Ph.D.
    Dr. Yann Jamin, Ph.D. Product Manager at Scintica
    Dr. Yann Jamin, Ph.D.
    Dr. Yann Jamin, Ph.D.
    Product Manager at Scintica

    Yann has 20 years of experience delivering practical and translational MRI solutions for the evaluation of novel cancer therapeutics and the study of tumour microenvironment at the ICR. As a part of the Preclinical MRI team led by Prof. Simon Robinson at the Centre of Cancer Imaging, Yann led on the integration of MRI within the mouse hospital protocols including the establishment of the shared MRI screening capabilities within the acquisition of the Aspect M-Series M3 MRI in 2016. In 2014, Yann was awarded a Children with Cancer UK Research fellowship and has since led a cross-disciplinary translational programme of research focusing on childhood neuroblastoma: His group has successfully incorporated computational pathology methods to demonstrate that the integration of functional and molecular MRI-biomarkers can provide quantitative data typically acquired from histological analysis. These “virtual” biopsies can potentially inform on the spatial and temporal heterogeneity associated with cancer evolution and resistance to treatment both at molecular and histological scales.

    In 2022, Yann joined Scintica Instrumentation, where he continues to apply his expertise and passion for MRI to enable more labs to benefit from the unique compact preclinical MRI that is the M-Series.

  • Dr. Evon Poon, Ph.D.
    Dr. Evon Poon, Ph.D. Senior Scientist, Paediatric Solid Tumour Biology Team, Division of Clinical Studies, The Institute of Cancer Research, London
    Dr. Evon Poon, Ph.D.
    Dr. Evon Poon, Ph.D.
    Senior Scientist, Paediatric Solid Tumour Biology Team, Division of Clinical Studies, The Institute of Cancer Research, London

    Evon is a senior scientist in the Paediatric Solid Tumour Biology Team led by Prof. Louis Chesler. A biochemist by training, Evon leads on the lab efforts to identify and evaluate the efficacy and mechanism of action of molecularly-targeted drugs that specifically target neuroblastoma cells with elevated levels of MYCN oncoprotein. She also manages and coordinate the extensive portfolio of preclinical trials within the mouse hospital and continue to foster the many collaborations with academic and industry partners which are contributing to make a significant impact to the lives of children with cancer.

Register

Explore our Past Webinars